The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial | BMC Cancer | Full Text

The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial | BMC Cancer | Full Text

The efficacy of a leukotriene receptor antagonist in the treatment of human rectal aberrant crypt foci: a nonrandomized, open-label, controlled trial

Leukotriene receptor antagonists (LTRAs) are broadly used for the management of allergic asthma and have recently been indicated to inhibit carcinogenesis and cancer cell growth. In colorectal cancer (CRC) che...

Authors:Takuma Higurashi, Jun Arimoto, Keiichi Ashikari, Tomohiro Takatsu, Noboru Misawa, Tsutomu Yoshihara, Tetsuya Matsuura, Akiko Fuyuki, Hidenori Ohkubo and Atsushi Nakajima

Citation:BMC Cancer 2020 20:770

Content type:Study protocol

 

Published on: 17 August 2020

• ViewFull Text
 
• ViewPDF